6z9v
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ==== | + | ==Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV== |
- | <StructureSection load='6z9v' size='340' side='right'caption='[[6z9v]]' scene=''> | + | <StructureSection load='6z9v' size='340' side='right'caption='[[6z9v]], [[Resolution|resolution]] 2.01Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6z9v]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z9V OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z9V FirstGlance]. <br> |
- | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z9v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z9v OCA], [https://pdbe.org/6z9v PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z9v RCSB], [https://www.ebi.ac.uk/pdbsum/6z9v PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z9v ProSAT]</span></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.01Å</td></tr> |
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=P4G:1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE'>P4G</scene>, <scene name='pdbligand=PE8:3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL'>PE8</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z9v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z9v OCA], [https://pdbe.org/6z9v PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z9v RCSB], [https://www.ebi.ac.uk/pdbsum/6z9v PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z9v ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/A0A140T913_HUMAN A0A140T913_HUMAN] | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The human CD8(+) T cell clone 6C5 has previously been shown to recognize the tert-butyl-modified Bax(161-170) peptide LLSY(3-tBu)FGTPT presented by HLA-A*02:01. This nonnatural epitope was likely created as a by-product of fluorenylmethoxycarbonyl protecting group peptide synthesis and bound poorly to HLA-A*02:01. In this study, we used a systematic approach to identify and characterize natural ligands for the 6C5 TCR. Functional analyses revealed that 6C5 T cells only recognized the LLSYFGTPT peptide when tBu was added to the tyrosine residue and did not recognize the LLSYFGTPT peptide modified with larger (di-tBu) or smaller chemical groups (Me). Combinatorial peptide library screening further showed that 6C5 T cells recognized a series of self-derived peptides with dissimilar amino acid sequences to LLSY(3-tBu)FGTPT. Structural studies of LLSY(3-tBu)FGTPT and two other activating nonamers (IIGWMWIPV and LLGWVFAQV) in complex with HLA-A*02:01 demonstrated similar overall peptide conformations and highlighted the importance of the position (P) 4 residue for T cell recognition, particularly the capacity of the bulky amino acid tryptophan to substitute for the tBu-modified tyrosine residue in conjunction with other changes at P5 and P6. Collectively, these results indicated that chemical modifications directly altered the immunogenicity of a synthetic peptide via molecular mimicry, leading to the inadvertent activation of a T cell clone with unexpected and potentially autoreactive specificities. | ||
+ | |||
+ | Synthetic Peptides with Inadvertent Chemical Modifications Can Activate Potentially Autoreactive T Cells.,Man S, Redman JE, Cross DL, Cole DK, Can I, Davies B, Hashimdeen SS, Reid R, Llewellyn-Lacey S, Miners KL, Ladell K, Lissina A, Brown PE, Wooldridge L, Price DA, Rizkallah PJ J Immunol. 2021 Aug 15;207(4):1009-1017. doi: 10.4049/jimmunol.2000756. Epub 2021 , Jul 28. PMID:34321228<ref>PMID:34321228</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 6z9v" style="background-color:#fffaf0;"></div> | ||
+ | |||
+ | ==See Also== | ||
+ | *[[MHC 3D structures|MHC 3D structures]] | ||
+ | *[[MHC I 3D structures|MHC I 3D structures]] | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: | + | [[Category: Man S]] |
+ | [[Category: Redman JE]] | ||
+ | [[Category: Rizkallah PJ]] |
Current revision
Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV
|